News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Thompson Matthew
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/28/2022 |
4
| Thompson Matthew (Director) has filed a Form 4 on Vivos Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $0.48, valued at
$14.4k
|
|
| 08/10/2021 |
4
| Thompson Matthew (Director) has filed a Form 4 on Vivos Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $2.72, valued at
$81.6k
|
|
| 08/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/07/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/01/2019 |
4
| Thompson Matthew (Chief Medical Officer) has filed a Form 4 on ENDOLOGIX INC /DE/|
Txns:
| Disposed/sold 8,999 options to buy
@ $48.2, valued at
$433.8k
Disposed/sold 9,907 options to buy
@ $69.1, valued at
$684.6k
Granted 6,304 options to buy
@ $4.71, valued at
$29.7k
|
|
| 08/06/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/10/2019 |
4
| Thompson Matthew (Chief Medical Officer) has filed a Form 4 on ENDOLOGIX INC /DE/|
Txns:
| Granted 1,250 shares
@ $0
Paid exercise price by delivering 421 shares
@ $6.4, valued at
$2.7k
|
|
| 02/01/2019 |
4
| Thompson Matthew (Chief Medical Officer) has filed a Form 4 on ENDOLOGIX INC /DE/|
Txns:
| Granted 19,142 shares
@ $0 |
|
| 01/02/2019 |
4
| Thompson Matthew (Chief Medical Officer) has filed a Form 4 on ENDOLOGIX INC /DE/|
Txns:
| Disposed/sold 15,000 shares
@ $0
Granted 470,115 shares
@ $0
Granted 225,621 options to buy
@ $0.7445, valued at
$168k
|
|
| 06/01/2018 |
4
| Thompson Matthew (Chief Medical Officer) has filed a Form 4 on ENDOLOGIX INC /DE/|
Txns:
| Granted 31,000 shares
@ $0
Paid exercise price by delivering 10,719 shares
@ $4.87, valued at
$52.2k
|
|
|
|